Based on 7 analysts giving stock ratings to Acrivon Therapeutics Inc in the past month.
In the current month, ACRV has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ACRV average Analyst price target in the last month is 12.200.
Based on analysts' estimates, ACRV EPS is projected to reach -0.444 in FY2026Q3, following reported EPS of -0.429 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.43, while Acrivon Therapeutics IncACRV's earnings per share (EPS) for the previous quarter was USD -0.49. EPS for the next quarter is expected at USD -0.44.